ELYM - Eliem Therapeutics, Inc. Stock Price, Fair Value and News

$3.25+0.19 (+6.21%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ELYM Price Action

Last 7 days

-20.6%

Last 30 days

-39.9%

Last 90 days

-51.1%

Trailing 12 Months

22.9%

ELYM RSI Chart

ELYM Valuation

Market Cap

218.5M

Price/Earnings (Trailing)

-3.16

Price/Sales (Trailing)

53.93

Price/Free Cashflow

-19.88

ELYM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ELYM Fundamentals

ELYM Revenue

Revenue (TTM)

5.1M

Rev. Growth (Yr)

49%

Rev. Growth (Qtr)

-0.59%

ELYM Earnings

Earnings (TTM)

-69.1M

Earnings Growth (Yr)

-124.17%

Earnings Growth (Qtr)

83.79%

ELYM Profitability

Return on Equity

-31.59%

Return on Assets

-31.11%

Free Cashflow Yield

-5.03%

ELYM Investor Care

Shares Dilution (1Y)

143.81%

Diluted EPS (TTM)

-2.12

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	5.1M	0	0	0
2023	2.2M	3.0M	3.8M	4.6M
2022	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

WEBSITE	https://eliemtx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	30

Eliem Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Eliem Therapeutics, Inc.? What does ELYM stand for in stocks?

ELYM is the stock ticker symbol of Eliem Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eliem Therapeutics, Inc. (ELYM)?

As of Tue Nov 19 2024, market cap of Eliem Therapeutics, Inc. is 218.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ELYM stock?

You can check ELYM's fair value in chart for subscribers.

Is Eliem Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ELYM is over valued or under valued. Whether Eliem Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Eliem Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELYM.

What is Eliem Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Nov 19 2024, ELYM's PE ratio (Price to Earnings) is -3.16 and Price to Sales (PS) ratio is 53.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELYM PE ratio will change depending on the future growth rate expectations of investors.